Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
Starbucks (SBUX) plans to close 250 underperforming North American cafes, expecting $300M in restructuring charges and lowering its fiscal 2026 net new store opening forecast. Analysts view the move positively. Eli Lilly (LLY) gained FDA approval for its weekly insulin Onswik, though its impact on sales is expected to be minimal. Lilly shares rose 3%. Costco (COST) reports earnings after the bell, with focus on membership metrics and margins.
How this was made
The 30-second read
Why it matters
Starbucks' store closures and Lilly's FDA approval provide fresh corporate catalysts that could move their stocks today.
Market read
Both companies are large‑cap U.S. stocks; the news offers actionable insight for traders in consumer and healthcare sectors.
What to watch
Potential supply‑chain constraints for Starbucks and competitive pricing pressure on Lilly's insulin from Novo Nordisk.
Background
The CNBC Investing Club afternoon update covers mixed market action, Treasury yields, and macro headlines alongside company-specific news.
Ticker impact
Starbucks announced closure of ~250 underperforming North American stores, $300M restructuring charge and lowered FY2026 store opening forecast.
Potential short‑term upside as investors price in cost savings.
Store closures are a clear corporate action that reduces expenses; market typically rewards such moves.
FDA approved Eli Lilly's once‑weekly insulin Onswik for type‑2 diabetes, adding a new product to its portfolio.
Limited upside; stock may see a small bump on the approval news.
FDA approvals are material but the drug is expected to contribute <1% of 2030 sales.
Market effects
Starbucks' restructuring may signal broader retail‑restaurant cost‑cutting trends; Lilly's approval highlights continued innovation in diabetes care.
U.S. consumer‑discretionary sentiment could improve if Starbucks' margins rise; pharma sector may see modest uplift.
Both events are U.S.-focused but could influence global investors tracking consumer and healthcare stocks.
Counterpoint
Starbucks closures could hurt brand perception and lead to short‑term sales dip; Lilly's new insulin may cannibalize existing products.
Key entities
- CompanyStarbucks
Coffee retailer implementing store closures.
- CompanyEli Lilly
Pharmaceutical firm receiving FDA approval for Onswik insulin.
